Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.The U.S. Food and Drug Administration had said on Monday it has approved generic versions of Vyvanse from 11 drugmakers after Takeda's exclusivity over the drug expired on Aug. 24. Copycats of the drug come in capsules and chewable tablets, ranging between 10 milligrams to 70 milligram doses.Also Read | Takeda brings to India drug for rare genetic condition U.S.-based drugmakers Mallinckrodt and...
Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine...